APEIRON’s „Three questions to“
Prof. Chris Oostenbrink 1. How can computational techniques allow to study the effects of mutations of SARS-CoV-2 ? Computational methods allow us to describe molecular interactions at a space and time resolution that is often unattainable experimentally. This means that we can zoom in at an atomic level to understand visualize, rationalize, and predict what...
July 15, 2021
No Comments
APEIRON Biologics launches next clinical trial with innovative cancer therapy APN401

Important development step for promising cell therapy Paradigm shift in cancer treatment: process developed by APEIRON uses immune system to treat solid tumors Innovative new manufacturing and treatment process enables outpatient treatment within one day from cell collection to reinfusion Phase Ib clinical trial evaluates immunological effects as well as safety and tolerability of APN401…

July 6, 2021
No Comments
APEIRON’s „Three questions to“
Prof. Ali Mirazimi, Karolinska Institutet, Department of Laboratory Medicine, Sweden 1. Given your background working with vaccines and contagious viruses, what surprised you most when the new coronavirus struck in March 2020 ? Most surprising was the broad arsenal of disease complexity and how the virus could very quickly cause a pandemic disease with huge...
June 14, 2021
No Comments
APEIRON Biologics Announces Changes to Management and Supervisory Boards

Management Board to be expanded by Romana Gugenberger, PhD, as Chief Medical & Scientific Officer (CMSO) and Andreas Gerber, PhD, as Chief Operating Officer (COO) Prof. Josef Penninger moves from the Supervisory Board to the newly created Scientific Advisory Board, which he will build up and lead as Chairman Additional pre-clinical data show highly promising…

June 1, 2021
No Comments
ACE2 – locking the door against coronaviruses?
Over a year after its emergence, COVID-19 continues to remain a global plague. Even with the development of vaccines, we see the pandemic caused by SARS-CoV-2 to stay with us for a while. With the identification of major new virus variants of concern hailing from the United Kingdom, South Africa, and Brazil with improved binding...
May 27, 2021
No Comments
APEIRON Biologics’ APN01 selected for large-scale US trial in COVID-19
APEIRON ́s APN01 to participate in US Phase 2 COVID-19 trial ACTIV-4d RAAS Further clinical study in preparation with inhalative drug delivery of APN01 to directly target respiratory tract and lung tissue Additional pre-clinical data show highly promising results with APN01 in various mutation variants Financing round planned to secure funding of further upcoming development...
May 19, 2021
No Comments
SARS-CoV-2 and herd immunity – will the virus always be one step ahead ?
‘Herd immunity’ and vaccine strategy The concept of ‘herd immunity’ is massively important in terms of disease transmission and overall efficacy of vaccine strategies. It relies on a certain proportion of a population having immunity against a disease, thus protecting those who are unable to receive vaccines. If vaccinated individuals stop the spread of infection,...
April 14, 2021
No Comments
APEIRON’s APN01 shows clinical benefits for severely ill COVID-19 patients in phase 2 trial
Treatment was safe and well tolerated and no drug-related severe adverse events were observed Significant improvement in mechanical ventilator-free Days and reduction in viral RNA load observed Biomarker development supports APN01’s mode of action against SARS-CoV-2 Investigators and experts recommend further development of APN01 in COVID-19 Press release (EN) | Presseaussendung (DE)
March 12, 2021
No Comments